Skip to main content

Chanakya

Integris Medtech IPO

Published: 20 November 2026 | 6.00 AM
Last Updated: 20 November 2026 | 6.00 AM

Integris Medtech IPO Snapshot

Integris Medtech IPO Snapshot

Particulars Details
Chanakya recommendation Wait for pricing
Overall rating 3/5, provisional
IPO opens on 27 November 2026
IPO closes on 1 December 2026
Allotment date 2 December 2026
Refund date 3 December 2026
Shares credited to demat accounts 3 December 2026
Listing date 4 December 2026
Price band To be announced
Face value Rs. 1 per share
Lot size To be announced
Minimum retail application Lots, shares and investment amount to be announced
Total IPO size Pending pricing
Fresh issue size Up to Rs. 600 crore
Fresh issue shares Pending pricing
Offer for sale (OFS) Up to 1,08,37,266 shares
OFS value Pending pricing
Total shares offered Pending pricing
Pre-IPO shares outstanding 10,83,38,049 shares
Unofficial GMP Unverified as of 20 November 2026
Subscription status Yet to open
Listing exchanges BSE and NSE Mainboard
Lead managers ICICI Securities, Axis Capital, Citigroup Global Markets India and IIFL Capital Services
Registrar KFin Technologies

The IPO timetable is tentative and subject to exchange confirmation.

The offer structure and intermediaries are disclosed in the draft prospectus and its addendum.

Investor Decision Box

Investor consideration Chanakya assessment
Listing gains Wait for the price band and institutional subscription.
Long-term investment Watchlist candidate, subject to valuation on recurring earnings.
Overall risk Medium to high, given past losses, borrowing volatility and acquisition integration.

👉 IPO GMP | IPO Reviews | IPO Subscription | IPO Allotment

Chanakya View

Wait for the price band. Integris Medtech’s FY25 operating revenue rose 22.5%, and the company returned to profit after two loss-making years. The June 2025 quarter’s Rs. 267.57 crore PAT included a Rs. 239.62 crore exceptional gain from the deemed disposal of investments. Post-issue P/E at the upper band is pending pricing and the final share count. Sahajanand Medical Technologies provides a cardiovascular reference and Molbio Diagnostics a diagnostics reference. The price relative to updated recurring earnings will determine the call.

About the Company

Integris Medtech develops, manufactures and sells cardiovascular devices, including drug-eluting stents and drug-coated balloons. Its laboratory business supplies instruments, reagents and consumables, alongside installation, maintenance and calibration services. It manufactures in India, Germany and the Netherlands and serves over 9,500 laboratories and 2,000 hospitals and catheterisation labs. Overseas markets contributed nearly 65% of FY25 operating revenue.

Why This IPO Stands Out

  • Recurring demand potential. Laboratory consumables and servicing can generate repeat business after instrument placement.
  • Improving operating profitability. FY25 EBITDA rose 62.5%, and EBITDA margin increased from 12.26% to 16.26%.

Key Risks

  • Earnings volatility. Exceptional gains and charges have materially affected reported profit across periods.
  • Borrowing swings. Debt more than doubled in FY25 before falling sharply by June 2025. Updated cash flows will help assess whether the reduction is durable.
  • Acquisition integration. Combining overseas businesses adds operating complexity across markets.

Financial Snapshot (Rs. Crore)

Restated consolidated FY23 FY24 FY25 Q1 FY26
Operating revenue 1,348.10 1,553.38 1,902.47 485.25
EBITDA 168.82 190.45 309.40 78.73
PAT −40.54 −4.88 70.68 267.57
Net worth 2,629.52 2,681.02 2,752.52 3,889.99
Borrowings 556.54 813.10 1,729.46 793.42

FY25 EBITDA grew faster than operating revenue, while borrowings rose to 5.6 times EBITDA at year-end.

Business Quality Score

Parameter Chanakya score
Business model 4/5
Industry outlook 4/5
Financial performance 3/5
Management 3/5
Balance sheet 2.5/5
Growth potential 4/5
 

IPO Proceeds and Why They Matter

Proposed useAmount
Repay or prepay borrowings of wholly owned subsidiariesRs. 93.87 crore
Repay or prepay borrowings of step-down subsidiariesRs. 415.98 crore
Total earmarked for debt repaymentRs. 509.85 crore
General corporate purposesAmount to be finalised

The debt allocation represents about 85% of the proposed Rs. 600 crore fresh issue before expenses. The two repayment amounts are components of the total. Lower debt could ease interest costs. OFS proceeds go to the selling promoter.

Business Outlook

The clearest growth opportunity is selling more reagents, consumables and services to laboratories already using Integris equipment. Cardiovascular devices provide another avenue through its hospital network. Integrating acquired businesses across markets will test management’s ability to convert that scale into cash. After listing, track operating cash flow, interest costs and EBITDA margins to assess whether operating improvements and debt repayment translate into sustainable earnings.

Strengths vs Concerns

StrengthsConcerns
Installed laboratory equipment supports repeat consumables and service sales.Acquisition integration can complicate execution.
FY25 EBITDA grew faster than operating revenue.Exceptional items have materially affected reported profit.

Who Should Apply?

Investor typeChanakya assessment
Listing-gain investorsWait for pricing and institutional subscription.
Long-term investorsConsider if recurring earnings support the offer valuation.
Conservative investorsPrefer evidence of sustained cash generation after listing.
Higher-risk investorsReassess once pricing and updated financials are available.

Chanakya Final Verdict

Wait for pricing. Provisional rating: 3/5. The proposed debt repayment could reduce financing costs, while the FY25 margin improvement supports the operating case. The June 2025 quarter’s profit included a substantial exceptional gain, making recurring earnings the more useful valuation benchmark. For listing gains, look for reasonable pricing and strong institutional demand. For long-term investment, assess the upper-band post-issue P/E using updated recurring earnings and check whether operating cash flow supports the improvement in margins.

Frequently Asked Questions

Should you apply for the Integris Medtech IPO?
Wait for the price band and assess valuation against recurring earnings.

When does the Integris Medtech IPO open and close?
The tentative subscription window is 27 November to 1 December 2026.

What is the minimum investment in the Integris Medtech IPO?
The amount depends on the price band and minimum bid lot, both awaited.

Short Summary

Integris Medtech combines cardiovascular devices with laboratory solutions. Debt repayment could strengthen its balance sheet. Chanakya’s call remains wait for pricing and assess valuation against recurring earnings.

Leave a Reply

Your email address will not be published. Required fields are marked *